The Experts below are selected from a list of 119604 Experts worldwide ranked by ideXlab platform
Robert K Zeldin - One of the best experts on this subject based on the ideXlab platform.
-
the effect of a losartan based Treatment Regimen on isolated systolic hypertension
Journal of Clinical Hypertension, 2002Co-Authors: William C Cushman, William E Brady, Lisa P Gazdick, Robert K ZeldinAbstract:This study was conducted to compare the antihypertensive efficacy and tolerability, over 12 weeks, of a losartan-based Treatment Regimen and placebo in patients with isolated systolic hypertension. Three hundred eight patients ≥35 years of age with isolated systolic hypertension, defined as trough sitting blood pressure between 140 and 200 mm Hg systolic and between 70 and 89 mm Hg diastolic, were randomized to losartan 50 mg (n=157) or placebo (n=151) once daily, with titration as necessary to achieve a goal trough sitting systolic blood pressure (SBP) <140 mm Hg. At baseline, mean trough sitting SBP was 140–159 mm Hg in 20.5% of patients, 160–179 mm Hg in 62.7%, and 180–200 mm Hg in 16.9%, and was similar in the two groups (losartan, 165.3 mm Hg; placebo, 166.1 mm Hg). At 12 weeks, mean trough sitting SBP decreased significantly (p<0.001) in both the losartan-based Treatment group (by 19.2 mm Hg) and in the placebo group (by 7.6 mm Hg). The reduction in sitting SBP was significantly greater for losartan than placebo (−11.6 mm Hg; 95% confidence interval, −14.8 to −8.4). In patients with isolated systolic hypertension, a once-daily losartan-based Treatment Regimen significantly lowered SBP. The losartan-based Regimen exhibited antihypertensive efficacy that was superior to that of placebo, with a similar tolerability profile.
-
The effect of a losartan-based Treatment Regimen on isolated systolic hypertension.
Journal of Clinical Hypertension, 2002Co-Authors: William C Cushman, William E Brady, Lisa P Gazdick, Robert K ZeldinAbstract:This study was conducted to compare the antihypertensive efficacy and tolerability, over 12 weeks, of a losartan-based Treatment Regimen and placebo in patients with isolated systolic hypertension. Three hundred eight patients ≥35 years of age with isolated systolic hypertension, defined as trough sitting blood pressure between 140 and 200 mm Hg systolic and between 70 and 89 mm Hg diastolic, were randomized to losartan 50 mg (n=157) or placebo (n=151) once daily, with titration as necessary to achieve a goal trough sitting systolic blood pressure (SBP)
William C Cushman - One of the best experts on this subject based on the ideXlab platform.
-
the effect of a losartan based Treatment Regimen on isolated systolic hypertension
Journal of Clinical Hypertension, 2002Co-Authors: William C Cushman, William E Brady, Lisa P Gazdick, Robert K ZeldinAbstract:This study was conducted to compare the antihypertensive efficacy and tolerability, over 12 weeks, of a losartan-based Treatment Regimen and placebo in patients with isolated systolic hypertension. Three hundred eight patients ≥35 years of age with isolated systolic hypertension, defined as trough sitting blood pressure between 140 and 200 mm Hg systolic and between 70 and 89 mm Hg diastolic, were randomized to losartan 50 mg (n=157) or placebo (n=151) once daily, with titration as necessary to achieve a goal trough sitting systolic blood pressure (SBP) <140 mm Hg. At baseline, mean trough sitting SBP was 140–159 mm Hg in 20.5% of patients, 160–179 mm Hg in 62.7%, and 180–200 mm Hg in 16.9%, and was similar in the two groups (losartan, 165.3 mm Hg; placebo, 166.1 mm Hg). At 12 weeks, mean trough sitting SBP decreased significantly (p<0.001) in both the losartan-based Treatment group (by 19.2 mm Hg) and in the placebo group (by 7.6 mm Hg). The reduction in sitting SBP was significantly greater for losartan than placebo (−11.6 mm Hg; 95% confidence interval, −14.8 to −8.4). In patients with isolated systolic hypertension, a once-daily losartan-based Treatment Regimen significantly lowered SBP. The losartan-based Regimen exhibited antihypertensive efficacy that was superior to that of placebo, with a similar tolerability profile.
-
The effect of a losartan-based Treatment Regimen on isolated systolic hypertension.
Journal of Clinical Hypertension, 2002Co-Authors: William C Cushman, William E Brady, Lisa P Gazdick, Robert K ZeldinAbstract:This study was conducted to compare the antihypertensive efficacy and tolerability, over 12 weeks, of a losartan-based Treatment Regimen and placebo in patients with isolated systolic hypertension. Three hundred eight patients ≥35 years of age with isolated systolic hypertension, defined as trough sitting blood pressure between 140 and 200 mm Hg systolic and between 70 and 89 mm Hg diastolic, were randomized to losartan 50 mg (n=157) or placebo (n=151) once daily, with titration as necessary to achieve a goal trough sitting systolic blood pressure (SBP)
John W Baddley - One of the best experts on this subject based on the ideXlab platform.
-
a multicenter double blind trial of a high dose caspofungin Treatment Regimen versus a standard caspofungin Treatment Regimen for adult patients with invasive candidiasis
Clinical Infectious Diseases, 2009Co-Authors: Robert F Betts, Marcio Nucci, Deepak Talwar, Marcelo Gareca, Flavio Queiroztelles, Roger Bedimo, Raoul Herbrecht, Guillermo M Ruizpalacios, Joanne H Young, John W BaddleyAbstract:Background. The standard caspofungin Treatment Regimen (50 mg/day after a 70-mg dose on day 1) is effective and well tolerated for the Treatment of invasive candidiasis, but experience with higher doses of caspofungin is limited. We evaluated the safety and efficacy of caspofungin at 3 times the standard dosing Regimen. Methods. Patients with proven invasive candidiasis were randomized to receive a standard or high-dose (150 mg/day) caspofungin Treatment Regimen. Safety was assessed in all patients as treated. Efficacy was assessed as a secondary objective in a full-analysis-set population. A favorable overall response was defined as symptom resolution and microbiological clearance at the end of caspofungin therapy. Results. A total of 204 patients were included in the safety analysis (104 received the standard Regimen, and 100 received the high-dose Regimen), and 197 were included in the efficacy analysis (102 and 95 in the standard and high-dose Treatment groups, respectively). Patient demographic characteristics, neutropenia status (6.7% and 8.0% had neutropenia, respectively), and Acute Physiology and Chronic Health Evaluation II scores (mean, 16.5 and 17, respectively) were similar between Treatment groups. Significant drug-related adverse events occurred in 1.9% of patients receiving the standard Regimen and 3.0% of patients receiving the high-dose Regimen (difference, 1.1%; 95% confidence interval, -4.1% to 6.8%). The most-common drug-related adverse events in the standard and high-dose Treatment groups were phlebitis (3.8% and 2.0%, respectively), increased alkaline phosphatase level (6.9% and 2.0%, respectively), and increased aspartate transaminase level (4.0% and 2.0%, respectively). Overall, 71.6% of patients who received the standard Regimen and 77.9% of patients who received the high-dose Regimen had favorable overall responses (difference, 6.3%; 95% confidence interval, -5.9% to 18.4%; not statistically significant). Mortality at 8 weeks after therapy was similar between groups. Conclusions. Both caspofungin dosing Regimens were effective and well tolerated in patients with invasive candidiasis. No safety concerns were found for caspofungin at a dosage of 150 mg/day.
Maarten L Simoons - One of the best experts on this subject based on the ideXlab platform.
-
the consistency of the Treatment effect of an ace inhibitor based Treatment Regimen in patients with vascular disease or high risk of vascular disease a combined analysis of individual data of advance europa and progress trials
European Heart Journal, 2009Co-Authors: Jasper J Brugts, Toshiharu Ninomiya, Eric Boersma, Willem J Remme, M E Bertrand, Roberto Ferrari, Stephen Macmahon, John Chalmers, Maarten L SimoonsAbstract:Aims Angiotensin-converting enzyme (ACE) inhibitors have been shown to reduce cardiovascular risk in different groups of patients. Whether these effects can be generalized to the broad group of patients with vascular disease is unknown. Therefore, we undertook a combined analysis using individual data from ADVANCE, EUROPA, and PROGRESS to determine the consistency of the Treatment effect of perindopril-based Regimen in patients with vascular disease or at high risk of vascular disease. Methods and results We studied all-cause mortality and major cardiovascular outcomes during a follow-up of about 4 years in the 29 463 patients randomly assigned a perindopril-based Treatment Regimen or placebo. The perindopril-based Regimens were associated with a significant reduction in all-cause mortality [hazard ratio (HR) 0.89; 95% confidence interval (CI) 0.82–0.96; P = 0.006], cardiovascular mortality (HR 0.85; 95% CI 0.76–0.95; P = 0.004), non-fatal myocardial infarction (HR 0.80; 95% CI 0.71–0.90; P < 0.001), stroke (HR 0.82; 95% CI 0.74–0.92; P = 0.002), and heart failure (HR 0.84; 95% CI 0.72–0.96; P = 0.015). Results were consistent in subgroups with different clinical characteristics, concomitant medication use, and across all strata of baseline blood pressure. Conclusion This study provides strong evidence for a consistent cardiovascular protection with an ACE-inhibitor Treatment Regimen (perindopril–indapamide) by improving survival and reducing the risk of major cardiovascular events across a broad spectrum of patients with vascular disease.
Lisa P Gazdick - One of the best experts on this subject based on the ideXlab platform.
-
the effect of a losartan based Treatment Regimen on isolated systolic hypertension
Journal of Clinical Hypertension, 2002Co-Authors: William C Cushman, William E Brady, Lisa P Gazdick, Robert K ZeldinAbstract:This study was conducted to compare the antihypertensive efficacy and tolerability, over 12 weeks, of a losartan-based Treatment Regimen and placebo in patients with isolated systolic hypertension. Three hundred eight patients ≥35 years of age with isolated systolic hypertension, defined as trough sitting blood pressure between 140 and 200 mm Hg systolic and between 70 and 89 mm Hg diastolic, were randomized to losartan 50 mg (n=157) or placebo (n=151) once daily, with titration as necessary to achieve a goal trough sitting systolic blood pressure (SBP) <140 mm Hg. At baseline, mean trough sitting SBP was 140–159 mm Hg in 20.5% of patients, 160–179 mm Hg in 62.7%, and 180–200 mm Hg in 16.9%, and was similar in the two groups (losartan, 165.3 mm Hg; placebo, 166.1 mm Hg). At 12 weeks, mean trough sitting SBP decreased significantly (p<0.001) in both the losartan-based Treatment group (by 19.2 mm Hg) and in the placebo group (by 7.6 mm Hg). The reduction in sitting SBP was significantly greater for losartan than placebo (−11.6 mm Hg; 95% confidence interval, −14.8 to −8.4). In patients with isolated systolic hypertension, a once-daily losartan-based Treatment Regimen significantly lowered SBP. The losartan-based Regimen exhibited antihypertensive efficacy that was superior to that of placebo, with a similar tolerability profile.
-
The effect of a losartan-based Treatment Regimen on isolated systolic hypertension.
Journal of Clinical Hypertension, 2002Co-Authors: William C Cushman, William E Brady, Lisa P Gazdick, Robert K ZeldinAbstract:This study was conducted to compare the antihypertensive efficacy and tolerability, over 12 weeks, of a losartan-based Treatment Regimen and placebo in patients with isolated systolic hypertension. Three hundred eight patients ≥35 years of age with isolated systolic hypertension, defined as trough sitting blood pressure between 140 and 200 mm Hg systolic and between 70 and 89 mm Hg diastolic, were randomized to losartan 50 mg (n=157) or placebo (n=151) once daily, with titration as necessary to achieve a goal trough sitting systolic blood pressure (SBP)
